219 related articles for article (PubMed ID: 38215755)
1. Engineering human pluripotent stem cell lines to evade xenogeneic transplantation barriers.
Pizzato HA; Alonso-Guallart P; Woods J; Connelly JP; Fehniger TA; Atkinson JP; Pruett-Miller SM; Monsma FJ; Bhattacharya D
Stem Cell Reports; 2024 Feb; 19(2):299-313. PubMed ID: 38215755
[TBL] [Abstract][Full Text] [Related]
2. Engineering Human Pluripotent Stem Cell Lines to Evade Xenogeneic Transplantation Barriers.
Pizzato HA; Alonso-Guallart P; Woods J; Johannesson B; Connelly JP; Fehniger TA; Atkinson JP; Pruett-Miller SM; Monsma FJ; Bhattacharya D
bioRxiv; 2023 Jun; ():. PubMed ID: 37425790
[TBL] [Abstract][Full Text] [Related]
3. Natural Killer Cells Prevent the Formation of Teratomas Derived From Human Induced Pluripotent Stem Cells.
Benabdallah B; Désaulniers-Langevin C; Colas C; Li Y; Rousseau G; Guimond JV; Haddad E; Beauséjour C
Front Immunol; 2019; 10():2580. PubMed ID: 31787975
[TBL] [Abstract][Full Text] [Related]
4. Pluripotent stem cells are highly susceptible targets for syngeneic, allogeneic, and xenogeneic natural killer cells.
Dressel R; Nolte J; Elsner L; Novota P; Guan K; Streckfuss-Bömeke K; Hasenfuss G; Jaenisch R; Engel W
FASEB J; 2010 Jul; 24(7):2164-77. PubMed ID: 20145206
[TBL] [Abstract][Full Text] [Related]
5. Human Induced Pluripotent Stem Cells Are Targets for Allogeneic and Autologous Natural Killer (NK) Cells and Killing Is Partly Mediated by the Activating NK Receptor DNAM-1.
Kruse V; Hamann C; Monecke S; Cyganek L; Elsner L; Hübscher D; Walter L; Streckfuss-Bömeke K; Guan K; Dressel R
PLoS One; 2015; 10(5):e0125544. PubMed ID: 25950680
[TBL] [Abstract][Full Text] [Related]
6. Selective deletion of human leukocyte antigens protects stem cell-derived islets from immune rejection.
Parent AV; Faleo G; Chavez J; Saxton M; Berrios DI; Kerper NR; Tang Q; Hebrok M
Cell Rep; 2021 Aug; 36(7):109538. PubMed ID: 34407395
[TBL] [Abstract][Full Text] [Related]
7. Targeted Disruption of the β2-Microglobulin Gene Minimizes the Immunogenicity of Human Embryonic Stem Cells.
Wang D; Quan Y; Yan Q; Morales JE; Wetsel RA
Stem Cells Transl Med; 2015 Oct; 4(10):1234-45. PubMed ID: 26285657
[TBL] [Abstract][Full Text] [Related]
8. Generation of hypoimmunogenic human pluripotent stem cells via expression of membrane-bound and secreted β2m-HLA-G fusion proteins.
Shi L; Li W; Liu Y; Chen Z; Hui Y; Hao P; Xu X; Zhang S; Feng H; Zhang B; Zhou S; Li N; Xiao L; Liu L; Ma L; Zhang X
Stem Cells; 2020 Nov; 38(11):1423-1437. PubMed ID: 32930470
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of pluripotent stem cell-derived teratoma formation by small molecules.
Lee MO; Moon SH; Jeong HC; Yi JY; Lee TH; Shim SH; Rhee YH; Lee SH; Oh SJ; Lee MY; Han MJ; Cho YS; Chung HM; Kim KS; Cha HJ
Proc Natl Acad Sci U S A; 2013 Aug; 110(35):E3281-90. PubMed ID: 23918355
[TBL] [Abstract][Full Text] [Related]
10. MHC-matched induced pluripotent stem cells can attenuate cellular and humoral immune responses but are still susceptible to innate immunity in pigs.
Mizukami Y; Abe T; Shibata H; Makimura Y; Fujishiro SH; Yanase K; Hishikawa S; Kobayashi E; Hanazono Y
PLoS One; 2014; 9(6):e98319. PubMed ID: 24927426
[TBL] [Abstract][Full Text] [Related]
11. Generation of universal and hypoimmunogenic human pluripotent stem cells.
Ye Q; Sung TC; Yang JM; Ling QD; He Y; Higuchi A
Cell Prolif; 2020 Dec; 53(12):e12946. PubMed ID: 33174655
[TBL] [Abstract][Full Text] [Related]
12. Effects of histocompatibility and host immune responses on the tumorigenicity of pluripotent stem cells.
Dressel R
Semin Immunopathol; 2011 Nov; 33(6):573-91. PubMed ID: 21461989
[TBL] [Abstract][Full Text] [Related]
13. Expression of rat complement control protein Crry on tumor cells inhibits rat natural killer cell-mediated cytotoxicity.
Caragine TA; Imai M; Frey AB; Tomlinson S
Blood; 2002 Nov; 100(9):3304-10. PubMed ID: 12384431
[TBL] [Abstract][Full Text] [Related]
14. Humanized mouse models with endogenously developed human natural killer cells for in vivo immunogenicity testing of HLA class I-edited iPSC-derived cells.
Flahou C; Morishima T; Higashi N; Hayashi Y; Xu H; Wang B; Zhang C; Ninomiya A; Qiu WY; Yuzuriha A; Suzuki D; Nakamura S; Manz M; Kaneko S; Hotta A; Takizawa H; Eto K; Sugimoto N
Biochem Biophys Res Commun; 2023 Jun; 662():76-83. PubMed ID: 37099813
[TBL] [Abstract][Full Text] [Related]
15. Modulation of human mesenchymal stem cell immunogenicity through forced expression of human cytomegalovirus us proteins.
Soland MA; Bego MG; Colletti E; Porada CD; Zanjani ED; St Jeor S; Almeida-Porada G
PLoS One; 2012; 7(5):e36163. PubMed ID: 22666319
[TBL] [Abstract][Full Text] [Related]
16. Rat T cells express neither CD55 nor CD59 and are dependent on Crry for protection from homologous complement.
Hanna S; Spiller O; Linton SM; Mead RJ; Morgan B
Eur J Immunol; 2002 Feb; 32(2):502-9. PubMed ID: 11828367
[TBL] [Abstract][Full Text] [Related]
17. Heterelogous expression of mutated HLA-G decreases immunogenicity of human embryonic stem cells and their epidermal derivatives.
Zhao L; Teklemariam T; Hantash BM
Stem Cell Res; 2014 Sep; 13(2):342-54. PubMed ID: 25218797
[TBL] [Abstract][Full Text] [Related]
18. Adenovirus E3/19K promotes evasion of NK cell recognition by intracellular sequestration of the NKG2D ligands major histocompatibility complex class I chain-related proteins A and B.
McSharry BP; Burgert HG; Owen DP; Stanton RJ; Prod'homme V; Sester M; Koebernick K; Groh V; Spies T; Cox S; Little AM; Wang EC; Tomasec P; Wilkinson GW
J Virol; 2008 May; 82(9):4585-94. PubMed ID: 18287244
[TBL] [Abstract][Full Text] [Related]
19. Multipotent adult germ-line stem cells, like other pluripotent stem cells, can be killed by cytotoxic T lymphocytes despite low expression of major histocompatibility complex class I molecules.
Dressel R; Guan K; Nolte J; Elsner L; Monecke S; Nayernia K; Hasenfuss G; Engel W
Biol Direct; 2009 Aug; 4():31. PubMed ID: 19715575
[TBL] [Abstract][Full Text] [Related]
20. Fit-For-All iPSC-Derived Cell Therapies and Their Evaluation in Humanized Mice With NK Cell Immunity.
Flahou C; Morishima T; Takizawa H; Sugimoto N
Front Immunol; 2021; 12():662360. PubMed ID: 33897711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
